AR044774A1 - Composiciones farmaceuticas de atorvastatina - Google Patents

Composiciones farmaceuticas de atorvastatina

Info

Publication number
AR044774A1
AR044774A1 ARP040102008A ARP040102008A AR044774A1 AR 044774 A1 AR044774 A1 AR 044774A1 AR P040102008 A ARP040102008 A AR P040102008A AR P040102008 A ARP040102008 A AR P040102008A AR 044774 A1 AR044774 A1 AR 044774A1
Authority
AR
Argentina
Prior art keywords
atorvastatin
compositions
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
Prior art date
Application number
ARP040102008A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR044774A1 publication Critical patent/AR044774A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Una composición farmacéutica granulada en húmedo que comprende atorvastatina o una de sus sales farmacéuticamente aceptables con menos de aproximadamente 5 % en peso de un aditivo constituido por una sal de metal alcalino-térreo con un desintegrante, que proporciona la atorvastatina con no más de aproximadamente 3 % de lactona de atorvastatina, basada en la relación del área del pico de lactona comparada con las áreas integradas de todos los picos relacionados con el fármaco, así como dicha composición farmacéutica granulada en húmedo que comprende atorvastatina o una de sus sales farmacéuticamente aceptables en combinación con al menos otro fármaco activo, métodos para preparar dichas composiciones, kits para contener dichas composiciones, y un método de tratar hipercolesterolemia y/o hiperlipidemia, osteoporosis, hiperplasia prostática benigna (BPH), y la enfermedad de Alzheimer que comprende una cantidad terapéuticamente eficaz de las composiciones farmacéuticas.
ARP040102008A 2003-06-12 2004-06-10 Composiciones farmaceuticas de atorvastatina AR044774A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47811903P 2003-06-12 2003-06-12

Publications (1)

Publication Number Publication Date
AR044774A1 true AR044774A1 (es) 2005-10-05

Family

ID=33551806

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102008A AR044774A1 (es) 2003-06-12 2004-06-10 Composiciones farmaceuticas de atorvastatina

Country Status (15)

Country Link
EP (1) EP1635814A1 (es)
JP (1) JP2006527260A (es)
KR (1) KR100814218B1 (es)
CN (1) CN100434069C (es)
AR (1) AR044774A1 (es)
AU (1) AU2004246868B2 (es)
BR (1) BRPI0411344A (es)
CA (1) CA2465565A1 (es)
CO (1) CO5650230A2 (es)
MX (1) MXPA05013281A (es)
NO (1) NO20060022L (es)
NZ (1) NZ543337A (es)
RU (1) RU2332211C2 (es)
TW (1) TW200503690A (es)
WO (1) WO2004110431A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
EP2170294A1 (en) * 2007-06-25 2010-04-07 Pharmathen S.A. Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
KR20100125346A (ko) * 2008-02-27 2010-11-30 토멘 메디칼 아게 임플란트 및 이의 제조 방법
ES2855426T3 (es) * 2008-09-17 2021-09-23 Mylan Inc Granulados, proceso de preparación de los mismos y productos farmacéuticos que los contienen
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
IN2014CN04119A (es) 2011-11-15 2015-07-10 Reddys Lab Ltd Dr
CN104069078B (zh) * 2014-05-22 2019-06-11 西藏九瑞健康股份有限公司 阿托伐他汀钙药物组合物及其制备方法
MX2017001177A (es) * 2014-07-25 2017-05-01 Novartis Ag Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin- 6-ylmetil) imidazo[1,2,b] [1,2,4]triazin-2-il]benzamida.
KR101658350B1 (ko) * 2015-02-06 2016-09-30 경성대학교 산학협력단 고지혈증 치료에 유용한 약학 조성물
BR112017019364B1 (pt) * 2015-03-12 2023-03-21 Dupont Nutrition Usa, Inc Dispersões sólidas e forma de dosagem de fármacos
CA3019508A1 (en) 2016-03-31 2017-10-05 Intercept Pharmaceuticals, Inc. Oral preparation having exceptional elutability

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0680320B1 (en) * 1993-01-19 1999-04-14 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
JPH06242003A (ja) * 1993-02-12 1994-09-02 Nkk Corp 鉄鋼中のアルミナの粒度測定方法
JP3014040B2 (ja) * 1996-10-30 2000-02-28 信久 川野 食物繊維パン及びその製造法
CA2406574C (en) * 2000-04-10 2006-12-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
EP1226818A1 (en) * 2001-01-26 2002-07-31 Pfizer Products Inc. Pharmaceutical dosage forms with enhanced cohesive and compressibility properties
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij

Also Published As

Publication number Publication date
JP2006527260A (ja) 2006-11-30
MXPA05013281A (es) 2006-03-09
WO2004110431A1 (en) 2004-12-23
CN100434069C (zh) 2008-11-19
CA2465565A1 (en) 2004-12-12
BRPI0411344A (pt) 2006-07-11
KR100814218B1 (ko) 2008-03-17
AU2004246868B2 (en) 2008-01-17
CO5650230A2 (es) 2006-06-30
AU2004246868A1 (en) 2004-12-23
KR20060020666A (ko) 2006-03-06
RU2005136745A (ru) 2006-07-27
RU2332211C2 (ru) 2008-08-27
CN1805741A (zh) 2006-07-19
NO20060022L (no) 2006-01-03
TW200503690A (en) 2005-02-01
NZ543337A (en) 2008-03-28
EP1635814A1 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
AR044775A1 (es) Composiciones farmaceuticas de atorvastatina
LU93078I2 (fr) Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
AR044774A1 (es) Composiciones farmaceuticas de atorvastatina
TW200607807A (en) Macrocyclic beta-secretase inhibitors
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
GT200500098A (es) Nuevos compuestos
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
NO20060149L (no) Farmasoytiske forbindelser av atorvastatin
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
CL2009000241A1 (es) Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
AR058780A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
ECSP066313A (es) Derivados de la piridazina y su uso como agentes terapéuticos
ECSP066315A (es) Derivados de la piridazina y su uso como agentes terapéuticos
AR041089A1 (es) Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
BRPI0518299A2 (pt) ciclopentanonas 2,3,4-substituÍdas como agentes terapÊuticos
BRPI0508975A (pt) formas de dosagem e composições farmacêuticas
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure